Introduction Quality of life studies indicate that overactive bladder (OAB) has a greater negative impact on everyday life than other serious conditions such as diabetes. The detrimental effect of OAB on female sexual health is more prominent than urinary incontinence. We know that tolterodine immediate release (IR) has a beneficial effect on urinary symptoms in OAB. Aim To evaluate the impact of tolterodine IR on sexual function in patients with OAB. Methods A total of 30 sexually active women with OAB from 20 to 52 years were included. All patients filled out the International Consultation on Incontinence Questionnaire (ICIQ) and the Arizona Sexual Experience Scale (ASEX) before treatment with tolterodine IR and at the end of each month of treatment until 3 months. Main Outcome Measures Expected outcomes were improvements in the ICIQ and ASEX total score. All ASEX items were expected to improve individually. These improvements indicate better sexual function after treatment. Results The mean of the total ASEX score improved relative to baseline in the first (P < 0.01), second (P < 0.01), and third (P < 0.01) follow-up. The mean of scores for sexual desire, arousal, vaginal lubrication, orgasm, and orgasm satisfaction improved significantly (P < 0.01) with each follow-up. Conclusion Tolterodine IR significantly improves sexual function of women with OAB. Improvement is seen in all domains of sexual function.

Study was aimed at comparing clinical and transperineal ultrasound findings of females with stress urinary incontinence and normal controls. Between 2004 and 2005, 40 women with stress urinary incontinence (mean age 47.5 years) diagnosed by history via ICIQ-SF (International consultation on Incontinence Questionnaire-Short Form) and 40 healthy female volunteers without any incontinence or LUTS (mean age 42.1 years) underwent transperineal ultrasonography for determination of posterior urethrovesical (beta) angle, bladder neck funneling and hypermobility of urethra. These findings were compared between patients and controls with regard to clinical data. Beta angle wider than 130 degrees, bladder neck funneling and hypermobility of urethra with transperineal ultrasonography were more common among cases than controls. LR (Likelihood Ratio) for urinary incontinence of these parameters was 2.5, 2.1 and 2, respectively. Perineal ultrasonography is highly associated with clinical findings. Hypermobility of urethra had highest sensitivity for diagnose of stress urinary incontinence but the specificity of bladder neck funneling in perineal sonography was higher.

ObjectiveTo compare the effects of tamsulosin and prazosin on clinical and urodynamic parameters in women with voiding dysfunction.MethodsForty women aged 20–65 years with a clinical diagnosis of voiding dysfunction were blindly randomized to two equal groups for treatment with tamsulosin 0.4 mg or 1–2 mg of prazosin daily. Symptom assessment with the American Urological Association Symptom Score (AUASS) and urodynamic evaluation was performed initially and after three months of treatment. Patient satisfaction was evaluated and severe adverse drug effects recorded. Statistical analysis was carried out using the Student’s t-test and Mann–Whitney U test.ResultsAlthough AUASS improved in both groups, the rate of improvement was larger in the tamsulosin group. Urodynamic parameters improved but did not normalize in both groups. Adverse side effects from medication in the prazosin group were more common than in the tamsulosin group. Most of the patients in the tamsulosin group (80%) were satisfied with their treatment compared with those in the prazosin group (45%).ConclusionTamsulosin and prazosin are both effective in palliating symptoms of women with voiding dysfunction and improving their urodynamic parameters. Tamsulosin may be the preferred drug to prescribe because of its more amenable side effect profile and greater patient satisfaction.

No abstract